Ahead of an FDA advisory committee meeting, Grail’s stock jumped as briefing materials posted by the agency suggested the regulator may take a favorable view of Galleri. The test is already available as a lab-developed diagnostic, but FDA approval could be a pivot point for Medicare and commercial reimbursement and broader clinical uptake. The FDA’s limited public commentary in the pre-adcomm materials raised expectations among investors and other stakeholders, with the advisory panel’s input typically carrying weight even when the agency is not required to follow it. Grail’s outcome now hinges on the panel discussion and the FDA’s final decision. For payers and clinical labs, the key question is whether evidence packages align with FDA’s benefit-risk framing and whether performance supports consistent reimbursement criteria. The adcom timetable keeps commercial and regulatory stakeholders tightly synced to next-step agency signaling.